Home > Oncology > ASCO 2020 > Gastrointestinal Cancer > HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan

Expert
Prof. Salvatore Siena, University of Milan Niguarda Cancer Center, Italy
Conference
ASCO 2020
Trial
Phase 3, DESTINY-CRC01
Featured video: A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.   In an initial report of patients with heavily pre-treated metastatic, HER2-expressing colorectal cancer (mCRC), preliminary efficacy was observed with trastuzumab deruxtecan, particularly in patients with the highest degree of HER2 positivity. Prof. Salvatore Siena (University of Milan Niguarda Cancer Center, Italy) presented results from the DESTINY-CRC01 study, which stratified 3 cohorts of patients [1]. Cohort A had HER2-overexpressing patients who had scores of 3 or higher according to immunohistochemistry testing (IHC 3 plus), as well as a score above 2 by in situ hybridisation (ISH). Cohort B were patients whose tumours...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on